iDNA vaccines and methods for using the same
AssigneeMedigen, Inc.
InventorsPeter Pushko, Igor Lukashevich
Life of this patent
Estimating the term…
Abstract
Described herein are iDNA vectors and vaccines and methods for using the same. The iDNA generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly yellow fever virus and Venezuelan equine encephalitis virus. When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient's tissues. This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus.
Claims16
A homogeneous clonally pure live attenuated virus prepared from cultured cells transfected with a vector comprising DNA encoding:
- (a) an infectious RNA molecule that encodes a non-pathogenic alphavirus;
- and (b) two RNA dependent RNA polymerase promoters;
- wherein the two RNA dependent RNA polymerase promoters are operatively linked to one or more portions of a capsid and a glycoprotein of the infectious RNA molecule.
A vaccine for an infectious RNA virus comprising a therapeutically effective amount of a homogeneous clonally pure live attenuated virus prepared from cultured cells transfected with a vector comprising DNA encoding:
- (a) an infectious RNA molecule that encodes a non-pathogenic alphavirus;
- and (b) two RNA dependent RNA polymerase promoters;
- wherein the two RNA dependent RNA polymerase promoters are operatively linked to one or more portions of a capsid and a glycoprotein of the infectious RNA molecule.
A homogeneous clonally purified live attenuated virus comprising:
- an infectious RNA molecule, and two RNA dependent RNA polymerase promoters, the two RNA dependent RNA polymerase promoters being operatively linked to one or more portions of a capsid and a glycoprotein of the infectious RNA molecule, wherein the infectious RNA molecule encodes a non-pathogenic alphavirus.
A method of producing a vaccine for an infectious RNA virus comprising transfecting cultured cells with a DNA vector comprising:
- (a) an infectious RNA molecule that encodes a non-pathogenic alphavirus;
- and (b) a eukaryotic RNA polymerase promoter;
- wherein the DNA encoding an infectious RNA molecule is operably linked to the RNA polymerase promoter.
A vaccine for an infectious RNA virus comprising a therapeutically effective amount of a DNA vector comprising DNA encoding:
- (a) an infectious RNA molecule that encodes an alphavirus;
- and
- (b) a eukaryotic RNA polymerase promoter;
- wherein the DNA encoding the infectious RNA molecule is operably linked to the RNA polymerase promoter.
A method for immunizing a mammal against an alphavirus comprising the step of administering to the mammal a vaccine comprising a therapeutically effective amount of a vector comprising:
- (a) an infectious RNA molecule that encodes a non-pathogenic alphavirus;
- and
- (b) a eukaryotic RNA polymerase promoter;
- wherein the DNA encoding an infectious RNA molecule is operably linked to the RNA polymerase promoter.
Dependencies are inferred from the claim text.